Farrell-Sherman, A.; Azam, W.; de la Force, N.; White, E. L.; Sandel, D. A.; Rodriguez, A. E.; Figueroa, T.; Dalhuisen, T.; Williams, M. C.; Tai, V.; Gruenhagen, G. W.; Abdellatif, A.; Fragiadakis, G. K.; Samghabadi, P.; De la Sancha Verduzco, C.; Vohra, P.; Gasper, C.; Long, S.; Caskey, M.; Zhu, B.; Shalek, A. K.; Hoh, R.; Rutishauser, R. L.; Peluso, M. J.; Deeks, S.; Cohn, L. B.

Sustained viral suppression following antiretroviral treatment (ART) cessation is a major goal of HIV cure research. Rare individuals mount immune responses able to control viral rebound without intervention, however, the earliest moments in which these responses form remain poorly defined. We performed an intensively sampled, prospective analytical treatment interruption (ATI) to study the initial immune response to rebound and to understand its role in defining subsequent virus control. Profiling of peripheral blood mononuclear cells and plasma revealed consistent immune activation prior to systemic rebound, including upregulation of antiviral transcriptional pathways, expansion of CD16++ non-classical monocytes, and increases of inflammatory and antiviral soluble plasma proteins. Individuals with prior viral control (controllers) diverged from non-controllers with a slower slope of rebound, a longer period of immune activity prior to rebound, and engagement of a multifaceted immune program with less systemic inflammation. An intermediate immune signature emerged in a separate ATI cohort of individuals who experienced delayed rebound after receiving broadly neutralizing antibodies, suggesting that immunotherapy can induce a potentially protective pre-rebound immune response. Together, these data resolve the earliest systemic host immune responses to HIV rebound and demonstrate broad immune differences associated with HIV control phenotypes.